Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:GTHXNASDAQ:OVIDNASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.26+4.6%$1.55$1.04▼$3.45$356.92M1.221.77 million shs3.04 million shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/AOVIDOvid Therapeutics$0.34+9.8%$0.55$0.30▼$3.45$24.17M0.44428,700 shs166,759 shsPEPGPepGen$1.46+11.5%$1.79$1.16▼$19.30$47.73M0.98797,136 shs219,102 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+4.56%-14.86%-1.56%-53.33%-41.40%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+55.43%OVIDOvid Therapeutics+9.78%-16.46%-31.08%-64.51%-88.85%PEPGPepGen+11.45%-7.01%-48.04%-61.27%-88.81%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.8933 of 5 stars4.51.00.00.03.73.31.3GTHXG1 Therapeutics0.4609 of 5 stars1.00.00.03.80.00.00.6OVIDOvid Therapeutics4.5409 of 5 stars3.53.00.04.62.64.20.6PEPGPepGen2.1884 of 5 stars3.22.00.00.01.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.83283.60% UpsideGTHXG1 Therapeutics 2.00Hold$4.00-44.06% DownsideOVIDOvid Therapeutics 3.00Buy$3.03792.16% UpsidePEPGPepGen 2.33Hold$10.33607.76% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, OVID, GTHX, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/24/2025OVIDOvid TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.003/21/2025ERASErascaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/21/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/12/2025OVIDOvid TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.003/7/2025ERASErascaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $4.002/24/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.001/30/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $16.001/29/2025OVIDOvid TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.001/7/2025ERASErascaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$2.10 per shareN/AGTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51OVIDOvid Therapeutics$566K42.70N/AN/A$1.24 per share0.27PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$125.04M-$0.74N/AN/AN/AN/A-42.26%-34.97%5/14/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/AOVIDOvid Therapeutics-$52.34M-$0.38N/AN/AN/A-5,142.56%-39.24%-26.19%5/13/2025 (Estimated)PEPGPepGen-$78.63M-$2.84N/AN/AN/AN/A-60.17%-48.88%5/13/2025 (Estimated)Latest PEPG, OVID, GTHX, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/11/2025Q4 2024OVIDOvid Therapeutics-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 million2/24/2025Q4 2024PEPGPepGen-$0.81-$0.68+$0.13-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0011.00GTHXG1 Therapeutics1.342.482.12OVIDOvid Therapeutics0.185.665.66PEPGPepGenN/A8.478.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%GTHXG1 Therapeutics24.21%OVIDOvid Therapeutics72.24%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipERASErasca21.50%GTHXG1 Therapeutics6.11%OVIDOvid Therapeutics13.30%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.27 million221.94 millionOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableOVIDOvid Therapeutics6071.08 million61.57 millionOptionablePEPGPepGen3032.69 million31.10 millionNot OptionablePEPG, OVID, GTHX, and ERAS HeadlinesRecent News About These CompaniesPepGen to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 4:05 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGApril 2 at 10:00 AM | accessnewswire.comPepGen names two new directors to boardApril 1 at 8:19 PM | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGApril 1 at 5:00 PM | accessnewswire.comPepGen Inc. Expands Board with New AppointmentsMarch 31 at 5:14 PM | tipranks.comPepGen Announces Appointment of Two New Directors to its BoardMarch 31 at 4:05 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 27, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 25, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 24, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 23, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 21, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 19, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 17, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 15, 2025 | accessnewswire.comShort Interest in PepGen Inc. (NASDAQ:PEPG) Expands By 229.6%March 14, 2025 | marketbeat.comPepGen Inc. Being Investigated on Behalf of PepGen Inc. Investors. Contact Levi & Korsinsky For DetailsMarch 13, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 13, 2025 | accessnewswire.comPepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceMarch 10, 2025 | businesswire.comPepGen Inc. (NASDAQ:PEPG) Short Interest Up 26.2% in FebruaryMarch 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGMarch 5, 2025 | accessnewswire.comPepGen to pause CONNECT2-EDO51 studyMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBest of Both Worlds: 3 ETFs With High Dividend Yields, Low FeesBy Nathan Reiff | March 26, 2025View Best of Both Worlds: 3 ETFs With High Dividend Yields, Low FeesWhat GTC 2025 Signals for NVIDIA Stock’s Next Big MoveBy Thomas Hughes | March 19, 2025View What GTC 2025 Signals for NVIDIA Stock’s Next Big MoveWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?Berkshire Hathaway Gains Defy Stock Market Slump By Jeffrey Neal Johnson | April 1, 2025View Berkshire Hathaway Gains Defy Stock Market Slump 3 High-Performing Tech ETFs to Diversify Your PortfolioBy Ryan Hasson | March 31, 2025View 3 High-Performing Tech ETFs to Diversify Your PortfolioPEPG, OVID, GTHX, and ERAS Company DescriptionsErasca NASDAQ:ERAS$1.26 +0.06 (+4.56%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.22 -0.04 (-3.57%) As of 04/2/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Ovid Therapeutics NASDAQ:OVID$0.34 +0.03 (+9.78%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.36 +0.02 (+4.41%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.PepGen NASDAQ:PEPG$1.46 +0.15 (+11.45%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.46 0.00 (-0.07%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
